- Genmab (Plainsboro, NJ)
- …candidates through IND enabling studies in close collaboration with Translational Research , Toxicology, DMPK, and other functionsManage clinical pharmacology, ... for a dynamic, science-driven people leader to head our Clinical Pharmacology & Quantitative Sciences team. Do you get...hybrid model that requires being onsite 60% of the time in Princeton, NJResponsibilitiesBuild, oversee and lead delivery of… more
- Genmab (Plainsboro, NJ)
- …market through collaboration with US Commercialization, Global Medical Affairs, Clinical Development, Regulatory, and other cross functional teams.We have a ... hybrid model that requires being in Princeton, NJ 60% of the time .ResponsibilitiesPartner with the indication strategy team lead to delivering the US Medical Affairs… more
- Genmab (Plainsboro, NJ)
- …RoleGenmab is looking for an experienced and passionate leader to be a part of our Global Regulatory Affairs (GRA) organization.In this role, the regulatory leader ... in our Princeton, NJ office which requires onsite presence 60% of the time per our hybrid policy.ResponsibilitiesReporting to the Team Lead of Regulatory Strategy,… more
- Formation Bio (New York, NY)
- …will manage a team of Clinical Trial Managers (CTMs) and Clinical Research Associates (CRAs) and will collaborate closely with cross-functional teams ... industry can progress because of the high cost and time of clinical trials. Recognizing that this...research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to… more
- Daiichi Sankyo, Inc. (Bernards, NJ)
- …focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.SummaryThe Director, Clinical ... Safety, will be a product safety lead or part of a product safety team, and be responsible...and provide safety leadership including but not limited to clinical studies, post-marketing surveillance, signal detection and management, important… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
- Formation Bio (New York, NY)
- …candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately ... research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to...values, and every team and individual plays a key part in our mission to bring new treatments to… more
